Suggestions
Idioma
metricas
Publish in this journal
Guide for authors
Searcher
Journal Information
Cite
Cite
Share
Download PDF
More article options
Carta científica
Available online 5 October 2026
Causas y evolución del colesterol LDL tras la suspensión del inclisirán en prevención secundaria
Causes and LDL cholesterol evolution after inclisiran discontinuation in secondary prevention
Visits
592
Elena Fuente González
Corresponding author
elenafuente99@hotmail.es

Autor para correspondencia.
, Francisco Romano Matos, Victoria Piro Mastracchio, María del Val Groba Marco, Mario Galván Ruiz, Antonio García Quintana
Servicio de Cardiología, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, España
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics

Article

These are the options to access the full texts of the publication REC: CardioClinics
Member
Socios SEC
Use datos de acceso a SEC en el menú Acceder.
Si es socio de la Sociedad Española de Cardiología y no puede acceder con sus claves, escriba a rec@cardioclinics.org.
Members of SEC
Use the Society's website login and password here.
If you are member of SEC and you have some problems with your login data, please contact with rec@cardioclinics.org.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to
REC: CardioClinics
Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Bibliografía
[1]
K.K. Ray, R.S. Wright, D. Kallend, et al.
Two phase3 trials of inclisiran in patients with elevated LDL cholesterol.
N Engl J Med., 382 (2020), pp. 1507-1519
[2]
K.K. Ray, R.P.T. Troquay, F.L.J. Visseren, et al.
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
Lancet Diabetes Endocrinol., 11 (2023), pp. 109-119
[3]
J.E. Blais, W. Zhong, C.Y.V. Li, C. Kongkaew, A.H.Y. Chan.
Adherence to PCSK9 inhibitors in clinical practice: systematic review and meta-analysis off observational studies.
JACC Adv., 5 (2026),
[4]
C.M. Ballantyne, T.E. Graham, L.J. van Anglen, et al.
Real-world adherence and effectiveness of inclisiran in lowering LDL-C: results from 1year of follow-up.
Cardiol Ther., 14 (2025), pp. 671-685
[5]
V. Piro, E. Fuente, F. Romano, et al.
Inclisiran for LDL-C reduction in secondary prevention: real-world evidence from a homogeneous Spanish cohort with subgroup insights.
Clin Investig Arterioscler., (2026),
[6]
K.K. Ray, R.M. Stoekenbroek, D. Kallend, et al.
Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial.
JAMA Cardiol., 4 (2019), pp. 1067-1075
Idiomas
REC: CardioClinics
Article options
Tools